Cookie Hinweis

Wir verwenden Cookies, um Ihnen ein optimales Webseiten-Erlebnis zu bieten. Dazu zählen Cookies, die für den Betrieb der Seite notwendig sind, sowie solche, die lediglich zu anonymen Statistikzwecken, für Komforteinstellungen oder zur Anzeige personalisierter Inhalte genutzt werden. Sie können selbst entscheiden, welche Kategorien Sie zulassen möchten. Bitte beachten Sie, dass auf Basis Ihrer Einstellungen womöglich nicht mehr alle Funktionalitäten der Seite zur Verfügung stehen. Weitere Informationen finden Sie in unseren Datenschutzhinweisen .

Essentiell

Diese Cookies sind für die Funktionalität unserer Website erforderlich und können nicht deaktiviert werden.

Name Webedition CMS
Zweck Dieses Cookie wird vom CMS (Content Management System) Webedition für die unverwechselbare Identifizierung eines Anwenders gesetzt. Es bietet dem Anwender bessere Bedienerführung, z.B. Speicherung von Sucheinstellungen oder Formulardaten. Typischerweise wird dieses Cookie beim Schließen des Browsers gelöscht.
Name econda
Zweck Session-Cookie für die Webanalyse Software econda. Diese läuft im Modus „Anonymisiertes Messen“.
Statistik

Diese Cookies helfen uns zu verstehen, wie Besucher mit unserer Webseite interagieren, indem Informationen anonym gesammelt und analysiert werden. Je nach Tool werden ein oder mehrere Cookies des Anbieters gesetzt.

Name econda
Zweck Measure with Visitor Cookie emos_jcvid
Externe Medien

Inhalte von Videoplattformen werden standardmäßig blockiert. Wenn Cookies von externen Medien akzeptiert werden, bedarf der Zugriff auf diese Inhalte keiner manuellen Zustimmung mehr.

Name Youtube
Zweck Externe Medien

DKFZ-MOST Cooperation in Cancer Research – List of all projects Ca 92 – Ca 164

Project phase 01.01.2001 – 31.12.2003
Ca-.No 092  Identification of NKp46 ligand: A ligand which is involved in the lysis of tumor cells and virally infected cells by natural killer cells
Ca-.No 093  A biochemical and molecular genetic approach to study the role of hepatocyte nuclear factor 4 (HNF4) and suppression of tumor development by fatty acids
Ca-.No 094  Modulation of the interaction of KGF with its receptor in normal and tumor cells
Ca-.No 095  The functional relevance of alterations in integrin alpha6beta4 and protein kinase C regulation in human and mouse skin carcinogenesis
Ca-.No 096  Novel anti-cancer vaccines based on oral application of recombinant Salmonella typhimurium bacteria
Ca-.No 097  Expansion of human hematopoietic stem cells and megakaryocyte progenitors for transplantation in cancer patients

Project phase 01.07.2002 – 30.06.2005
Ca-.No 098  Phenotypic reversal in multidrug resistant cancer cells
Ca-.No 099  Targeting the adenosine A3 receptor for the treatment and prevention of colon carcinoma: molecular mechanisms and preclinical evaluation
Ca-.No 100  The CD95 (APO-1/Fas) death system in tumor progression
Ca-.No 101  Involvement of c-Abl in HPV-induced carcinogenesis
Ca-.No 102  Tyrosine kinase VEGF receptors and neuropilins and the role of their VEGF and semaphoring ligands in tumor development and progression
Ca.-No 103  Human papillomavirus type 16 in cervical cancer: the potential role of E6 natural variants in regression of progression of viral-induced disease
Ca.-No 104  Functional significance of insulin signaling in skin and skin tumorigenesis
Ca.-No 105  Macromolecular polymers as a novel platform for the tumor directed delivery of drugs targeting molecular processes of apoptosis and radiation

Phase IX 01.01.2004 – 31.12.2006
Ca.-No 106  Identification of the genetic network controlled by the caudal transcriptional regulator
Ca.-No 107  The role of nuclear lamina proteins in organizing nuclear architecture in normal and transformed cells
Ca.-No 108  Influence of antigen receptor mediated signaling in apoptosis and survival during the selection of lymphocytes
Ca.-No 109  Functional and physical analysis of the IGF-I receptor gene in progression to advanced breast cancer
Ca.-No 110  Chromosomal fragile sites and cancer
Ca.-No 111  Oncogenic activity of HTLV-I Tax and its prevention
Ca.-No 112  Tumor-associated blood vessel endothelium as a barrier to infiltration of effector immunocytes

01.07.2004 – 31.12.2005
Ca.-No 113  Genotypes of drug transporting and metabolising genes as potential modifiers of cancer risk and chemotherapy-sensitivity
Ca.-No 114  New strategies in the treatment of osteolytic bone metastasis of mammary carcinoma
Ca.-No 115  The impact of host and tumor derived IL-1 on tumor growth and host defense
Ca.-No 116  Melanoma growth, anti-tumor immune response and inflammation: a critical three-lateral interrelationship for successful immunotherapy
Ca.-No 117  Molecular mechanisms driving HCC development in mouse model of hepatitis-associated cancer
Ca.-No 118  Evaluation of function for ligands of activating natural killer cells receptors in anti-tumor immunity
Ca.-No 119  Analysis of Alu exonization and alternative splicing in cancer genes
Ca.-No 120  Identification and functional analysis of protein phosphorylation and dephosphorylation in the ATM-mediated DNA damage response

Phase IX 01.01.2007 – 31.12.2009
Ca.-No 121  Hypomethylation-induced genetic instability as a factor in tumor formation
Ca.-No 122  Epigenetic mechanisms regulating transcriptions and genome stability in cancer cells
Ca.-No 123  Contribution of endoplasmic reticulum (ER) stress and mitochondrial perturbation in the death of breast and colon cancer cells induced by plant cytotoxic agents
Ca.-No 124  The role of DNA damage-mediated BID phosphorylation for TRAIL-induced apoptosis
Ca.-No 125  Identification and characterization of cytokinetic targets in cancer therapy
Ca.-No 126  High resolution assessment of antiogenesis and normalization of tumor vessel phenotype under therapy using implanted MR-coils and functional and molecular MR-imaging methods
Ca.-No 127  Human heparanase – a promising target for the development of therapeutic strategies in cancer

Phase X 01.07.2008 – 30.06.2011
Ca.-No 128  Inflammation-dependent immunosuppressive tumor microenvironment: Its neutralization for successful tumor immunotherapy
Ca.-No 129  Intracellular signalling pathways controlling cell fate decisions of lymphocytes during differentiation and tumorigenesis
Ca.-No 130  Molecular mechanisms of inflammation induced liver cancer
Ca.-No 131  Molecular pathways underlying apoptotic and non apoptotic cell death and their implication in cancer development
Ca.-No 132  Interplay between VEGF and angiopoietins in the vascular tumor microenvironment
Ca.-No 133  Exploring the network of STAT3 and MITF in melanoma using RNAi libraries
Ca.-No 134  The Cellular pathways leading to cancer

Phase X 01.07.2009 – 30.06.2012
Ca.-No 135  Regulation and function of viral and cellular microRNAs controlling the immune response
Ca.-No 136  Monochlonal antibodies targeting CD24 in the treatment of pancreatic cancer
Ca.-No 137  Regulation of p53 family tumor suppressors under DNA damage stress
Ca.-No 138  The complex interactions of semaphorins and the delta-notch pathway in tumor angiogenesis
Ca.-No 139  Defining control and function of alternative splicing during tumorigenesis

Phase X 01.07.2010 – 30.06.2013
Ca.-No 140  RTK-dependent cell death in pediatric tumors of neural origin
Ca.-No 141  The roles of SIL(STIL) in centrosome biology – relevance to cancer and developmental disorders
Ca.-No 142  Characterization and regulation of NCR and NKG2D ligands in cancer
Ca.-No 143  Interactions between cancer associated fibroblasts (CAFs) and myeloid-derived inflammatory cells in the dynamic phenotype of the microenvironment during tumor progression; basic mechanisms and preclinical applications of novel intervention strategies
Ca.-No 144  Heparanase: a promising target and tumor antigen for therapeutic strategies in cancer

Phase XI, gr 1 01.07.2011 - 30.06.2014
Ca.-No 145 A systems-level dissection of Telomere biology
Ca.-No 146 Identifying features of chromatin organiza­tion and epigenetic modifications associated with pluripotency and self-renewal in stem cells and tumor initiating cells
Ca.-No 147 Cross species inflammatory oncogenomics to identify therapeutic targets for liver cancer
Ca.-No 148 Control of CTL-mediated tumor rejection by regulatory T cells: Imaging and molecular mechanisms
Ca.-No 149 microRNA control of tissue invasion and intestinal cancer

Phase XI, gr 2 01.07.2012 - 30.06.2015
Ca.-No 150 The DNA methylation program in inflammation cancer
Ca.-No 151 Modulation of regulatory T cell function by novel Treg-specific monoclonal antibodies
Ca.-No 152 Characterizing the role of the microenvironment in facilitating melanoma brain metastasis
Ca.-No 153 microRNA control of MSC and CAF in breast cancer: A proangiogenic switch and cell-remodeling
Ca.-No 154 Impact of the pro-inflammatory microenvironment on cellular programs of oncogene induced senescence during carcinogenesis

Phase XI, gr 3 01.07.2013 - 30.06.2016
Ca.-No 155 Folate deficiency and human papilloma virus-induced carcinogenesis
Ca.-No 156 Quantitative analysis of Delta-Notch membrane distributions and its regulation during angiogenesis and metastasis
Ca.-No 157 The role of CCR5 in the recruitment of myeloid-derived suppressor cells (MDSC) from the bone marrow to support melanoma progression
Ca.-No 158 Function of the lipid phospatase MTMR7 in anti-EGFR therapy resistance of colorectal cancer (CRC)
Ca.-No 159 Exploring microRNA transfer and melanoma progression: novel concept of cell-cell communication in the tumor microenvironment

Phase XII, gr 1 01.07.2014 - 30.06.2017
Ca.-No 160 Dissecting the contribution of vimentin intermediate filaments to mechanical and structural properties of cancer cells, using advanced physical approaches
Ca.-No 161 Molecular regulation of cellular fate by p53: the choice between apoptosis and senescence
Ca.-No 162 The role of the quiescence inducer Slfn2, in T-ALL development
Ca.-No 163 Tumor suppressive mechanisms of micro RNA 122*
Ca.-No 164 Identification of anticancer immune checkpoint molecules expressed by tumor cells or lymphocytes using high-throughput RNAi screening
Gr.-No 2495 Developing dual PAR1/KLK6 inhibitors based on bi-specific APPI peptide-small molecule conjugates for clinical translation as therapeutic anticancer agents
Gr.-No 2511 Unraveling driver mutations and epigenetic alterations in pediatric solid tumors

to top
powered by webEdition CMS